Novartis provides drug candidate compounds to TB Alliance
- Details
- Category: Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.
FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.(1)
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
Allied Minds and Bristol-Myers Squibb form new enterprise
- Details
- Category: Bristol-Myers Squibb
Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) have announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.
Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark. Santaris Pharma has pioneered its proprietary Locked Nucleic Acid (LNA) platform that has contributed to an emerging era of RNA-targeting therapeutics.
Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
- Details
- Category: Pfizer
Pfizer Inc. has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.
More Pharma News ...
- AstraZeneca agrees strategic transaction with Almirall in respiratory disease
- Bayer continues positive business development
- Bristol-Myers Squibb reports second quarter 2014 financial results
- Merck strengthens commitment to Chinese growth market
- MedImmune and Advaxis partner on immuno-oncology combination clinical trial
- AstraZeneca reveals designs for new Global R&D Centre and Corporate Headquarters in Cambridge, UK
- Novartis maintained strong innovation momentum in second quarter